-
Nov 15, 2024 | 
acrjournals.onlinelibrary.wiley.com | Murray Baron |Quebec Canada |Mandana Nikpour |Dylan Hansen
Supporting Information Filename Description acr25467-sup-0001-Disclosureform.pdfPDF document, 356.6 KB Disclosure Form acr25467-sup-0002-Tables.zipZip archive, 37.1 KB Supplementary Tables
-
Oct 18, 2024 | 
acrjournals.onlinelibrary.wiley.com | Laura Taylor |Dylan Hansen |Kathleen Morrisroe |Jessica Fairley
Supporting Information Filename Description acr25452-sup-0001-Disclosureform.pdfPDF document, 1.2 MB Disclosure form acr25452-sup-0002-Supinfo.docxWord 2007 document , 36.3 KB Appendix S1: Supplementary Information REFERENCES 1, , , et al. Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology (Oxford) 2021; 60: 3121–3133. 2, , , et al.
-
Sep 19, 2024 | 
lupus.bmj.com | Yanjie Hao |Dylan Hansen |Worawit Louthrenoo |Yi-Hsing Chen
DiscussionAttainment of low disease activity in SLE is included in the updated EULAR recommendations for SLE as a treatment target.22 LLDAS is the most widely accepted and validated23–27 low disease activity end point for SLE. According to the definition of LLDAS, major organ system activity such as renal, central nervous system, cardiopulmonary, vasculitis, fever, haemolytic anaemia or gastrointestinal activity is excluded.
-
Sep 3, 2024 | 
acrjournals.onlinelibrary.wiley.com | Laura Ross |Melbourne Victoria |Dylan Hansen |Susanna Proudman
Supporting Information Filename Description acr25427-sup-0001-Disclosureform.pdfPDF document, 687.5 KB Disclosure Form acr25427-sup-0002-supinfo.docxWord 2007 document , 54.2 KB Supporting Information
-
Jun 27, 2024 | 
acrjournals.onlinelibrary.wiley.com | Laura Ross |Dylan Hansen |Susanna Proudman |Rheumatology Unit
Supporting Information Filename Description art42939-sup-0001-Disclosureform.pdfPDF document, 368.6 KB Disclosure Form art42939-sup-0002-Supinfo.docxWord 2007 document , 152.9 KB Appendix S1: Supporting Information
-
Jun 20, 2024 | 
digitalcommons.library.tmc.edu | Jessica Fairley |Dylan Hansen |Laura Ross |Susanna Proudman
To describe the clinical phenotype and prognosis of people in the Australian Scleroderma (SSc) Cohort Study with pulmonary arterial hypertension (PAH) with or without interstitial lung disease (ILD). Participants meeting ACR/EULAR criteria for SSc were divided into four mutually exclusive groups: those meeting criteria for PAH (PAH-only), ILD (ILD-only), concurrent PAH and ILD (PAH-ILD) or neither PAH nor ILD (SSc-only).
-
May 21, 2024 | 
digitalcommons.library.tmc.edu | Laura Ross |Dylan Hansen |Nancy Maltez |Kathleen Morrisroe
AbstractDigital ulcers (DU) are a common, severe vascular manifestation of systemic sclerosis (SSc) with few effective treatment options.
-
May 1, 2024 | 
jrheum.org | Jessica Fairley |Dylan Hansen |Andrew Burns |David Prior
Contribution of Left Ventricular Diastolic Dysfunction to Survival and Breathlessness in Systemic Sclerosis–Associated Interstitial Lung Disease Jessica L. Fairley, Dylan Hansen, Andrew Burns, David Prior, André La Gerche, Kathleen Morrisroe, Wendy Stevens, Mandana Nikpour, Laura J. Ross The Journal of Rheumatology May 2024, 51 (5) 495-504; DOI: 10.3899/jrheum.2023-0801
-
Apr 1, 2024 | 
acrjournals.onlinelibrary.wiley.com | Kate Gregory |Dylan Hansen |Ross Penglase |Diane Apostolopoulos
INTRODUCTION Systemic sclerosis (SSc) is a condition characterized by inflammation, fibrosis, and vasculopathy of multiple organ systems, including the skin, heart, lungs, kidneys, and gastrointestinal tract. It causes significant functional impairment and reduced quality of life1, 2 and has a high mortality rate,3-5 predominantly due to SSc interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH).
-
Mar 25, 2024 | 
acrjournals.onlinelibrary.wiley.com | Zoe Brown |Zoé Brown |Dylan Hansen |Wendy Stevens |Nava Ferdowsi
INTRODUCTION In 2015, the European Society of Cardiology (ESC) and European Respiratory Society (ERS) guidelines recommended a multidimensional risk assessment tool to guide treatment decisions and prognostication in pulmonary arterial hypertension (PAH) (Table 1).1 The 2015 ESC risk assessment tool stratified prognostic variables according to cut points as having low, intermediate, or high risk of 1-year mortality.
